title: Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.
abstract: Pharmacokinetic models range from being entirely exploratory and empirical, to semi-mechanistic and ultimately complex physiologically based pharmacokinetic (PBPK) models. This choice is conditional on the modelling purpose as well as the amount and quality of the available data. The main advantage of PBPK models is that they can be used to extrapolate outside the studied population and experimental conditions. The trade-off for this advantage is a complex system of differential equations with a considerable number of model parameters. When these parameters cannot be informed from in vitro or in silico experiments they are usually optimized with respect to observed clinical data. Parameter estimation in complex models is a challenging task associated with many methodological issues which are discussed here with specific recommendations. Concepts such as structural and practical identifiability are described with regards to PBPK modelling and the value of experimental design and sensitivity analyses is sketched out. Parameter estimation approaches are discussed, while we also highlight the importance of not neglecting the covariance structure between model parameters and the uncertainty and population variability that is associated with them. Finally the possibility of using model order reduction techniques and minimal semi-mechanistic models that retain the physiological-mechanistic nature only in the parts of the model which are relevant to the desired modelling purpose is emphasized. Careful attention to all the above issues allows us to integrate successfully information from in vitro or in silico experiments together with information deriving from observed clinical data and develop mechanistically sound models with clinical relevance.
authors.affiliation: Centre for Applied Pharmacokinetic Research, Manchester Pharmacy School, University of Manchester, Manchester, UK.
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Tsamandouras
authors.forename: Amin
authors.initials: A
authors.lastname: Rostami-Hodjegan
authors.forename: Leon
authors.initials: L
authors.lastname: Aarons
mesh_terms: D001499:Bayes Theorem; D006801:Humans; D016247:Information Storage and Retrieval; D008954:Models, Biological; D010599:Pharmacokinetics
keywords: Bayesian analysis; PBPK; identifiability; middle-out approach; parameter estimation; population variability
references.citation: Clin Pharmacol Ther. 2012 Jul;92(1):50-61
references.pmid: 22644330
references.citation: J Pharmacokinet Pharmacodyn. 2002 Dec;29(5-6):473-505
references.pmid: 12795242
references.citation: Ann ICRP. 2002;32(3-4):5-265
references.pmid: 14506981
references.citation: Clin Pharmacol Ther. 1974 Jul;16(1):99-109
references.pmid: 4210517
references.citation: Toxicol Lett. 2001 Mar 31;120(1-3):411-20
references.pmid: 11323201
references.citation: Environ Health Perspect. 2000 Oct;108 Suppl 5:883-93
references.pmid: 11035998
references.citation: J Pharm Sci. 2006 Jun;95(6):1238-57
references.pmid: 16639716
references.citation: Chem Rev. 1998 Apr 2;98(2):391-408
references.pmid: 11848905
references.citation: Ann Pharmacother. 2004 Nov;38(11):1907-15
references.pmid: 15367729
references.citation: Expert Opin Drug Metab Toxicol. 2007 Apr;3(2):235-49
references.pmid: 17428153
references.citation: J Pharmacokinet Pharmacodyn. 2012 Feb;39(1):17-35
references.pmid: 22101761
references.citation: J Pharmacokinet Biopharm. 1980 Dec;8(6):633-48
references.pmid: 7229913
references.citation: Clin Pharmacokinet. 2006;45(9):931-56
references.pmid: 16928154
references.citation: J Pharm Sci. 2005 Jun;94(6):1259-76
references.pmid: 15858854
references.citation: In Silico Pharmacol. 2013 Jun 03;1:9
references.pmid: 25505654
references.citation: Pharm Res. 2013 Jun;30(6):1536-52
references.pmid: 23543304
references.citation: Am J Physiol. 1980 Jul;239(1):R7-24
references.pmid: 7396041
references.citation: Drug Metab Pharmacokinet. 2009;24(1):53-75
references.pmid: 19252336
references.citation: J Pharmacol Exp Ther. 2005 Jun;313(3):1254-62
references.pmid: 15743928
references.citation: Drug Metab Dispos. 2013 Apr;41(4):744-53
references.pmid: 23303442
references.citation: J Expo Sci Environ Epidemiol. 2010 Jun;20(4):326-41
references.pmid: 19471319
references.citation: Nat Rev Drug Discov. 2007 Feb;6(2):140-8
references.pmid: 17268485
references.citation: Pharm Res. 1993 Jul;10(7):1093-5
references.pmid: 8378254
references.citation: J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):711-23
references.pmid: 23179857
references.citation: J Pharm Pharmacol. 2012 Jul;64(7):1008-24
references.pmid: 22686346
references.citation: Toxicol Lett. 1993 Aug;69(2):181-96
references.pmid: 8212060
references.citation: Clin Pharmacokinet. 2008;47(4):245-59
references.pmid: 18336054
references.citation: J Pharmacokinet Pharmacodyn. 2006 Apr;33(2):97-124
references.pmid: 16550455
references.citation: Pharm Res. 2013 Mar;30(3):761-80
references.pmid: 23179780
references.citation: Toxicology. 2010 Dec 30;278(3):256-67
references.pmid: 20600548
references.citation: Clin Pharmacol Ther. 1974 Jul;16(1):87-98
references.pmid: 4210516
references.citation: J Pharmacokinet Pharmacodyn. 2006 Feb;33(1):1-27
references.pmid: 16369700
references.citation: Environ Health Perspect. 2000 May;108 Suppl 2:307-16
references.pmid: 10807560
references.citation: Bioinformatics. 2007 Oct 1;23(19):2612-8
references.pmid: 17660526
references.citation: J Pharmacokinet Biopharm. 1998 Feb;26(1):21-46
references.pmid: 9773391
references.citation: Clin Pharmacol Ther. 2011 Feb;89(2):259-67
references.pmid: 21191381
references.citation: J Pharmacokinet Pharmacodyn. 2006 Oct;33(5):571-94
references.pmid: 16810558
references.citation: J Pharmacokinet Biopharm. 1981 Oct;9(5):635-51
references.pmid: 7334463
references.citation: J Toxicol Environ Health B Crit Rev. 2008 Aug;11(7):519-47
references.pmid: 18584453
references.citation: J Pharmacokinet Pharmacodyn. 2006 Aug;33(4):421-39
references.pmid: 16568353
references.citation: Drug Metab Dispos. 2010 Feb;38(2):241-8
references.pmid: 19884323
references.citation: J Pharmacol Exp Ther. 2009 Feb;328(2):652-62
references.pmid: 19001154
references.citation: Br J Clin Pharmacol. 2005 Dec;60(6):581-3
references.pmid: 16305581
references.citation: J Pharmacokinet Biopharm. 1980 Dec;8(6):553-71
references.pmid: 7229908
references.citation: Clin Pharmacokinet. 2003;42(10):883-908
references.pmid: 12885263
references.citation: Curr Drug Metab. 2008 Nov;9(9):940-51
references.pmid: 18991591
references.citation: Br J Clin Pharmacol. 2005 Jun;59(6):691-704
references.pmid: 15948934
references.citation: Arch Toxicol. 2001 Jun;75(4):189-99
references.pmid: 11482516
references.citation: J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):613-28
references.pmid: 19936895
references.citation: Toxicol Ind Health. 1997 Jul-Aug;13(4):407-84
references.pmid: 9249929
references.citation: Eur J Clin Pharmacol. 2007 May;63(5):485-98
references.pmid: 17345074
references.citation: Crit Rev Toxicol. 1997 May;27(3):261-72
references.pmid: 9189655
references.citation: Fundam Appl Toxicol. 1995 Apr;25(1):29-44
references.pmid: 7601325
references.citation: J Pharmacokinet Pharmacodyn. 2010 Aug;37(4):365-405
references.pmid: 20661651
references.citation: J Psychopharmacol. 2006 Nov;20(6):842-9
references.pmid: 16714321
references.citation: Basic Clin Pharmacol Toxicol. 2010 Jan;106(1):2-12
references.pmid: 19686541
references.citation: Annu Rev Pharmacol Toxicol. 2011;51:45-73
references.pmid: 20854171
references.citation: In Silico Pharmacol. 2013 Apr 11;1:6
references.pmid: 25505651
references.citation: J Pharmacokinet Biopharm. 1997 Aug;25(4):413-47
references.pmid: 9561487
references.citation: J Pharmacokinet Pharmacodyn. 2005 Dec;32(5-6):719-36
references.pmid: 16341473